
In vivo dosimetry is a check of the radiotherapy treatment process. Recently, it has been argued that in vivo dosimetry at the start of every patient's radiotherapy is cost effective. We have examined and extended the cost effectiveness argument and show that the model does not deliver the stated benefits.

